The in vivo investigation demonstrated that OVV-CD19BiTE displayed selective replication within the tumor tissue, resulting in a notably augmented proportion of CD3, CD8, and naïve CD8 T subpopulations within the tumor, as compared to blinatumomab. The gene discussed is CD8A; the disease is neoplasm.